The FDA just approved a 'smart' pill that can track if you're taking your medication


The Food and Drug Administration just approved its first-ever pill containing electronic tracking sensors. The anti-psychotic drug Abilify MyCite, which treats bipolar disorder, schizophrenia, and depressive disorders, uses an electronic signal to record whether or not a patient ingested the pill, Gizmodo reported Tuesday.
When it touches stomach acid, the pill generates an electronic signal, which can be used to send data to medical professionals via a smartphone app and a Bluetooth signal. Sending data requires patients to first sign a consent form allowing their data to be shared with their doctors — as well as up to four selected friends and family members — and also wear a patch on their left rib cage that would transmit the information.
The New York Times notes, however, that patients can block data recipients whenever they choose to. That is potentially problematic, Dr. Jeffrey Lieberman, chairman of psychiatry at Columbia University and New York Presbyterian hospital, told the Times: "There's an irony in it being given to people with mental orders that can include delusions. It's like a biomedical Big Brother."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
While patients prone to paranoia may see malicious intent in electronic tracking of drug ingestion, there are significant benefits to being able to track whether or not patients are taking their medication. Studies have shown that people usually take only half of their prescribed doses when they are self-administering medication, and a 2013 study estimated that people not taking their pills properly costs the U.S. between $100 billion and $289 billion a year and leads to 125,000 deaths annually.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kelly O'Meara Morales is a staff writer at The Week. He graduated from Sarah Lawrence College and studied Middle Eastern history and nonfiction writing amongst other esoteric subjects. When not compulsively checking Twitter, he writes and records music, subsists on tacos, and watches basketball.
-
5 museum-grade cartoons about Trump's Smithsonian purge
Cartoons Artists take on institutional rebranding, exhibit interpretation, and more
-
Settling the West Bank: a death knell for a Palestine state?
In the Spotlight The reality on the ground is that the annexation of the West Bank is all but a done deal
-
Sudoku medium: August 23, 2025
The Week's daily medium sudoku puzzle
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year